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Summary Killing of autologous melanoma (auto-Me) was obtained with pooled allostimulated peripheral
blood lymphocytes (PBL) in 34/42 cases and found not to be due to a cross-reactivity between melanoma and
allogeneic normal antigens. To see whether generation of tumour cytotoxic PBL by allostimulation was due to
release of IL-2, PBL from 34 patients were divided into two aliquots and stimulated either by alloantigens or
IL-2. Allostimulated PBL were cytotoxic for auto-Me in 30/34 cases (85%) whereas IL-2 generated tumour
cytotoxic cells in 22/34 cases (64%). Lysis of K562, a target for monitoring NK-like activity, was obtained in
95-100% of cases with both stimuli. A similar frequency of OKT3+, OKT4+, OKT8+ and HNKl + cells was
found in PBL activated by allostimulation and IL-2, whereas a higher frequency of OKM1 + cells was evident
in IL-2-stimulated PBL. Cold-target competition studies indicated that allostimulation generated at least two
different types of effectors, one lytic to auto-Me but not to K562, and the other which lysed both targets.
Allostimulated, FACS-separated T3- cells killed both auto-Me and K562 cells whereas T3+ cells lysed only
auto-Me. It is concluded that allostimulation generated two subpopulations of auto-Me killer cells, one of the
T lineage and the other NK-like, which both can destroy auto-Me targets.
Proliferation and generation of tumour cytotoxic
lymphocytes in autologous mixed lymphocyte
tumour cell culture (MLTC) can be obtained in a
high percentage of tumour patients (Vanky et al.,
1982; Vose & Bonnard, 1982). In melanoma
patients, however, the activation of lymphocytes by
autologous melanoma cells (auto-Me) correlates
with the patients' clinical stage, since primary but
not metastatic melanoma cells are able to stimulate
autologous peripheral blood lymphocytes (auto-
PBL) (Fossati et al., 1984; Guerry et al., 1984).
Nevertheless, PBL from patients with primary or
metastatic melanoma as well as from patients with
tumours of different histologic origin can lyse auto-
logous tumour cells after in vitro activation with a
pool of allogeneic normal PBL (Zarling et al.,
1978b; Strausser et al., 1981; Fossati et al., 1982;
Mazumder et al., 1983). The pathway of the allo-
stimulation-induced killing of autologous tumour
cells is still unclear since different types of effectors
can be generated and expanded in mixed lympho-
cyte culture (MLC), including non-specific effectors
such as NK-like cells or lymphokine-activated killer
cells (LAK) (Grimm et al., 1982; Lopez-Bonet et
al., 1982; MacPhail et al., 1984). The cytotoxicity of
alloactivated patients' PBL (Pt-PBL) might be
specific and due either to a cross-reactivity between
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alloantigens and tumour cells (Zarling et al., 1978a;
Parmiani et al., 1979), or to the presence of T cells
previously sensitized in vivo to tumour-associated
antigens (TAA), and which are then activated and
expanded during the MLC through the release of
lymphokines, mainly interleukin 2 (IL-2) (Vose &
White, 1983). On the other hand, tumour cell lysis
could be due to activation by IL-2 of NK-like cells
which can lyse autologous and allogeneic tumour
cells, or of LAK cells which can kill also NK-
resistant fresh tumours (Grimm et al., 1982; Lotze
et al., 1981).
The present study was undertaken to investigate
the pathway of the MLC-generated auto-Me-cyto-
toxic PBL. We found that the lysis of auto-Me by
allostimulated Pt-PBL was not due to a cross-
reaction between TAA and alloantigens, and that
allostimulation leads to the generation of at least
two different types of effectors, the first of which
lyses auto-Me but not K562 targets and the second
which recognizes NK-sensitive structures both on
auto-Me and K562. The precursor cells of these
two types of effectors are T3+ and T3-
respectively.
Materials and methods
Peripheral blood tymphocytes (PBL)
PBL were obtained from heparinized blood of
cancer patients with metastatic melanoma between
10 and 15 days after surgery or from normal
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volunteers by fractionation on Ficoll-Ipaque. The
cells were washed twice and resuspended in
complete medium (CM) consisting of RPMI 1640
(M.A. Bioproducts, Walkersville, MD, USA)
containing 10% of heat-inactivated human AB
serum from healthy donors, 15mM Hepes buffer
(Gibco, Grand Island, NY, USA), 10OUml-m of
penicillin, 100ygmlP' of streptomycin and
glutamine. PBL were depleted of adherent cells by
incubation on plastic flasks for 2h at 37°C.
Tumour target cells
The preparation of tumour cells has been described
in detail elsewhere (Fossati et al., 1982). Briefly,
fresh tumour cells were obtained from lymph node
metastases of malignant melanoma patients. When
present, red blood cells were lysed by a 10min
treatment with ammonium chloride at 4°C and
dead cells were removed by treating the cell
suspension with 0.25% of trypsin and DNase
(240Uml-1) at room temperature for 1 min.
Tumour cells were frozen and stored in liquid
nitrogen. These cells were thawed when needed and
used as targets; in 20% of cases cultured melanoma
cells were used as targets within the first 3-4 in
vitro transfer generations. Both fresh cryopreserved
and cultured target cells were of .80% viability
when used as assessed by trypan blue exclusion,
and had <5% obvious contamination with non-
malignant cells. K562, the NK-sensitive myeloid
leukemia line, was cultured in CM and passaged
weekly. Serological tests with monoclonal anti-
bodies showed that our K562 line lacks MHC
antigens.
In vitro activation systems
Non-adherent (NA)-PBL (106ml 1) from
melanoma patients or normal donors were either
left in CM without stimulation or stimulated in
vitro in the following ways: (i) with irradiated
(40Gy) autologous tumour cells (auto-Me) at
different responder to stimulator cell ratios ranging
from 1:1 to 160:1 (MLTC); (ii) with an irradiated
pool of lymphocytes from 4-6 different donors at
1:1 ratio; (iii) with IL-2-containing supernatants
from allostimulated normal PBL or PHA-
stimulated, lectin free IL-2 (Associated Biomedics
System, Buffalo, NY, USA) at 20-40% final
concentration. The concentration of IL-2 was
selected after preliminary kinetics experiments.
Effector cells kept in 2ml of CM, using 24 wells
cluster plates (Costar, 3524, Cambridge, MA,
USA), were harvested after 6-7 days of incubation
at 37°C in a 5% CO2 and washed 3 times before
testing in 5'Cr-release assay.
5ICr-release assay
The cytotoxicity of in vitro stimulated lymphocytes
was tested against lymphocytes or tumour cells in
4h or 18h 51Cr-release assays. Briefly, different
numbers of effector lymphocytes were mixed with
5 x 103 tumour cells or 104 normal lymphocytes,
labelled with 200-400uCi Na2 51CrO4 (Radio-
chemical Center, Amersham, UK) in round-
bottomed 96 wells of microtiter plates (N. 650101,
CA Greiner and Shone, Niirtingen, FRG) in 0.2ml
final volume in CM. The plates were then
centrifuged and 0.1 ml of supernatant was collected
and counted in a gamma-scintillation counter
(Packard Instruments, La Grange, IL, USA). The
percentage of specific 5 Cr-release wis calculated
from the following formula:
% specific release
cpm release test
-cpm spontaneous release 100
cpm total incorporation
-cpm spontaneous release
All tests were performed in triplicate and the mean
+s.e. calculated; s.e. never exceeded 5% of the
mean. Only levels of cytotoxicity of 15% or more
above the SR were considered positive, which in
our experimental conditions corresponded to a level
of p<0.01. Spontaneous release was between 15
and 40%; values >40% were not considered.
Cold-target competition assay
Effector cells were incubated with labelled target
cells at a ratio of 25-40:1 and, simultaneously,
different numbers of unlabelled target cells were
added to give an inhibitor to target cell ratio of
10:1, 5:1 and 1:1. The cytotoxicity was then
measured at the end of 4h when tests were carried
out in parallel with lymphocytes and tumour cells,
and after 18h when targets and cold competitors
were K562 or melanoma cells. The results were
expressed as percentage of inhibition calculated as
follows:
( % specific lysis in the
-presence ofcompeting cells x 100
% specific lysis in the
absence of competing cells/
Cell surface markers
Monoclonal antibodies OKT3, OKT4, OKT8,
OKM1 were obtained from Ortho Pharmaceutical
Corporation (Raritan, NJ, USA) and monoclonal
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antibodies were used at saturating concentration as
previously determined. Immunofluorescence was
evaluated by a Cell Sorter (FACS IV, Becton
Dickinson, Mountain View, CA, USA). As for cell
separation, lymphocytes were incubated with OKT3
and then isolated by FACS into T3+ and T3- cells.
The purification was always >98%.
Results
Generation oflymphocytes cytotoxic to auto-Me by
allostimulation
Pt-PBL were stimulated either in autologous MLTC
or in MLC with a pool of lymphocytes from
normal donors (N-PBL) and then tested in a cell-
mediated cytotoxicity (CMC) assay against auto-
Me cells. Table I summarizes the results of these
experiments. Cytotoxicity to auto-Me was seen in
34/42 cases when Pt-PBL were stimulated with a
pool of allogeneic N-PBL but no lytic activity was
observed in 19/20 cases when Pt-PBL were cultured
with metastatic auto-Me cells (MLTC). This was
true even when different responder: tumour cell
ratios (from 1:1 to 160:1) were used, or when
purified T cells from Pt-PBL were adopted as
responder cells or when the assay of the same
patient was further repeated after a longer time
from surgery (data not shown).
Table I also shows that the reactivity of
unstimulated Pt-PBL was evident only in 3/27 cases
(11%) and that autologous PBL were never lysed
by allostimulated Pt-PBL, confirming previous
findings of our laboratory (Fossati et al., 1982).
Lysis of tumour cells by allostimulated Pt-PBL is
not due to cross-reactivity between allogeneic N-PBL
and melanoma cells
The above findings prompted us to investigate
whether autologous tumour lysis by allostimulated
Pt-PBL occurred through a cross-reactivity between
normal alloantigens and TAA as has been found
for some experimental neoplasms ((Parmiani et al.,
1979; Greenberg et al., 1981; Kedar et al., 1982a;
Sensi et al., 1983). To test this hypothesis, PBL
from 13 metastatic melanoma patients were
stimulated with allogeneic N-PBL from single
donors and then tested for cytotoxicity on auto-Me
and on the N-PBL used as stimulators. Table II
shows, as expected, that singly allostimulated Pt-
PBL effectors lysed stimulator cells in a high
percentage of cases (11/13), although these
allogeneic PBL were randomly selected without
previous HLA typing. Lysis of auto-Me cells was
obtained in 6/13 cases; in the negative cases auto-
Me cells were not intrinsically resistant to lysis
Table I Cytotoxicity of in vitro stimulated PBL of
melanoma patients (Pt-PBL)
No. ofpositive cases?
No. ofcases tested on
Responder Stimulus auto-Meb auto-PBLc
Pt-PBL Medium 3/27 0/6
auto-Me 1/20 0/6
allogeneic
N-PBLd 34/42 0/17
aThe cytotoxicity assay was considered positive when
> 15% specific 51Cr-release was observed at the
effector:target ratio of 40:1.
bauto-Me: autologous melanoma.
Cauto-PBL: autologous PBL.
dN-PBL: Pooled PBL from 4-6 normal donors.
Table II Tumour cytotoxicity of Pt-PBL stimulated with
allogeneic PBL from a single donor
% specific cytotoxicity on
Patient
no. auto-Mea auto-PBL' Stimulating PBL
9556 36c 3 16
3582 16 0 24
11573 26 NDd 18
4809 29 -3 48
5165 16 2 18
1954 18 ND 23
1582 4 7 18
8607 5 -2 36
395 0 0.5 28
9245 6 2 38
5979 2 3 39
4178 0 4 3
1076 4 1 9
aauto-Me: autologous melanoma.
bauto-PBL: autologous PBL.
C% Specific cytotoxicity in a 4h "Cr-release assay and
at effector:ratio of 40:1.
dNot done.
since they were killed by allogeneic PBL sensitized
against Pt-PBL (data not shown). Three different
patterns of reactivity were found (Table II). In 6
cases Pt-PBL lysed both auto-Me and stimulating
PBL, a finding compatible with antigens shared by
this group of melanomas and alloantigens of
stimulating N-PBL. In the second pattern (5 cases),
alloimmune Pt-PBL lysed the stimulating lympho-
cytes but not the auto-Me. This might be due to
lack of cross-reacting determinants between the
randomly selected stimulators and the melanoma
cells used. These results also indicate that the76 A. BALSARI et al.
generation of specific allocytotoxic lymphocytes is
not always associated with the activation of anti-
melanoma killer cells. In the last two cases neither
auto-Me nor stimulating PBL were killed, possibly
due to HLA sharing between responder and
stimulator cells or to a general unresponsiveness of
Pt-PBL. Autologous Pt-PBL were never lysed.
To further investigate whether the lysis of auto-
Me by Pt-PBL stimulated with N-PBL of a single
donor was due to a cross-reacting normal histo-
compatibility antigen present as an alien,
inappropriate determinant on melanoma cells, cold
target competition experiments were carried out.
Figure 1 (left panel) shows a representative
experiment in which auto-Me efficiently inhibited
the lysis of allostimulated Pt-PBL on auto-Me
whereas the stimulating PBL failed to block the
lysis. On the contrary, the cytotoxicity of singly
stimulated Pt-PBL against the stimulating PBL was
always inhibited by the stimulating PBL but not by
auto-Me (right panel). Similar results were obtained
in all 4 different cases examined. Thus, these data
tend to exclude the possibility that lysis of auto-Me
cells by alloactivated Pt-PBL was due to cross-
reacting alloantigens abnormally expressed by
neoplastic cells.
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Figure 1 Singly allostimulated Pt-PBL tested on auto-
e 3338 (a) and stimulating normal PBL (b). Inhibition
with auto-Me (0) and stimulating PBL (0). E:T ratio
25:1. Specific cytotoxicity of unblocked allostimulated
Pt-PBL was 48 and 39% on auto-Me and N-PBL
respectively.
Generation ofauto-Me cytotoxic cells by
allostimulation or exposure to IL-2
To investigate whether generation of tumour cyto-
toxic Pt-PBL by allostimulation may occur through
release of IL-2, PBL suspensions from each of 34
patients were divided into two aliquots which were
then stimulated either by alloantigens or by
exposure to IL-2-containing supernatants of MLC-
Table III Cytotoxicity of Pt-PBL stimulated by
allogeneic N-PBL or by IL-2
No. ofpositive cases?
No. ofcases tested on
Responder Stimulus auto-Meb auto-PBLc K562
Pt-PBL Medium 4/28 NDd ND
Allogeneic
N-PBLe 30/34 0/17 25/26
IL-2 22/34 0/15 22/22
aThe cytotoxicity assay was considered positive when
> 15% specific 51Cr-release was observed at the
effector:target ratio of40:1.
bauto-Me: autologous melanoma.
Cauto-PBL: autologous PBL.
dNot done. CN-PBL: Pooled PBL from 4-6 normal donors.
stimulated normal PBL or to lectin-free IL-2. The
pattern of reactivity of all cases tested is shown in
Table III. Pt-PBL stimulated by a pool of N-PBL
were cytotoxic to auto-Me in 30/34 cases (85%)
whereas IL-2 generated cytotoxic lymphocytes in
22/34 cases (64%). The direct comparison of the 34
cases examined shows that in 22 instances auto-Me
cells were similarly lysed by Pt-PBL activated by
either stimuli; auto-Me lysis was obtained by
activation with MLC but not with IL-2 in 8 cases.
In 4 cases auto-Me were not lysed by Pt-PBL
activated by either stimuli, although these targets
were regularly destroyed by alloactivated PBL from
normal donors.
Thus, in 78% of cases (26/34 of which 22 positive
and 4 negative) allostimulation and IL-2 gave
concordant patterns of reactivity on auto-Me.
Fresh or short-term cultured melanomas were
equally sensitive to the killing by MLC- or IL-2-
activated Pt-PBL (data not shown). It should be
noted that the lysis of K562, a tumour line used as
control for monitoring NK-like activity and which
is killed also by LAK cells (Grimm et al., 1982),
was obtained in 95-100% of cases by both stimuli.
The phenotype of alloactivated and IL-2-
activated effectors was evaluated in 8 patients using
monoclonal antibodies recognizing T3, T4, T8,
HNK1 and Ml determinants. A similar percentage
of T3+, T4+, T8+ and HNK1+ cells was found in
both lymphocyte populations, whereas a higher
frequency (51+7 vs 30+7) of M1+ cells was
evident in IL-2-activated Pt-PBL. The difference in
frequency of lysis (85 vs 64%) and of OKM1 + cells
between the two lymphocyte populations may
suggest the presence of different subsets of effector
PBL.ANTI-MELANOMA ALLOACTIVATED KILLER LYMPHOCYTES
Allostimulation generates different subsets ofeffector
cells
Since Pt-PBL cytotoxic for both K562 and auto-Me
cells can be generated by stimulating Pt-PBL with
alloantigens or IL-2, we decided to further analyze
this point by cold target competition experiments.
Pt-PBL were allostimulated in MLC or cultured
with IL-2 and then tested for cytotoxicity against
auto-Me in the presence of unlabelled auto-Me or
K562 competitor cells. As shown in Figure 2, where
one of the six experiments done is reported, auto-
Me but not K562 cells strongly inhibited the lysis
of auto-Me by allostimulated Pt-PBL whereas both
auto-Me and K562 cells blocked to the same extent
the lysis of IL-2-activated Pt-PBL on auto-Me
targets.
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Figure 2 Cytotoxicity on auto-Me 6538 by Pt-PBL
activated by allostimulation (a) or IL-2 (b). Inhibition
with auto-Me (0) and K562 (0) unlabelled cells. E:T
ratio 40:1. Specific cytotoxicity of unblocked allo-
stimulated or IL-2 stimulated Pt-PBL was 27 and 29%
respectively.
Other experiments were done using K562 as
target and both K562 and auto-Me as inhibitor
cells. Figure 3 includes 2 of the 5 experiments
which gave essentially similar results. As in Figure
2, auto-Me strongly inhibited the cytotoxicity of
allostimulated Pt-PBL on auto-Me targets, whereas
K562 cells gave a significantly lower (borderline)
inhibition at the same target to inhibitor cell ratio.
When alloactivated effectors of the same patient
were tested on K562, similar inhibition was
obtained with K562 and with auto-Me, although in
one case (N.11652) auto-Me gave a slightly higher
inhibition at 10-5: 1 inhibitor to target ratio,
Figure 3 Alloactivated Pt-PBL 10080 and 11652
tested on auto-Me and K562. Inhibition with auto-Me
(0) and K562 (0) unlabelled cells. E:T ratio 25:1.
Specific cytotoxicity of unblocked allostimulated Pt-
PBL (10080) on auto-Me and K562 was 52% and
49% respectively, and that of Pt-PBL (11652) on auto-
Me and K562 was 90% and 40% respectively.
whereas in all the other 4 cases (of which only
N.10080 is shown in the Figure) K562 usually
displayed a slightly better blocking effect.
These results indicate that allostimulation leads
to the generation of different types of effectors, one
which lyses auto-Me but not K562 targets and
another which recognizes NK-like sensitive
structures both on auto-Me and K562 cells.
Precursors ofalloactivated cytotoxic lymphocytes
Since the cold target inhibition experiments
suggested that effector lymphocytes able to
recognize and lyse auto-Me but not K562 targets
could be activated by allostimulation, we
investigated the precursor cells of such anti-tumour
cytotoxic lymphocytes. Pt-PBL were separated by
FACS into T3+ and T3- PBL and then stimulated
by a pool of allogeneic N-PBL. The purification of
T3+ and T3- cells was always >98%. After allo-
activation, the cytotoxicity of these populations was
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Table IV Precursor lymphocytesa of cytotoxic cells
allostimulated with N-PBL
% specific lysisb on
Experiment Responder auto-Mec K562
Exp. 1 Pt-PBL 38 63
Pt-T3+ 32 6
Pt-T3- 33 56
Exp. 2 Pt-PBL 21 40
Pt-T3 + 18 4
Pt-T3- 33 57
aPt-T3 + and -T3
- subpopulations were separated by
FACS before their use as responder in MLC; the
purification was always >98%.
b% Specific lysis in a S Cr-release assay at
effector:target ratio of 40:1 after 7 days of alloactivation
in MLC.
Cauto-Me: autologous melanoma.
tested on auto-Me and K562 targets. In 3 out of 4
experiments done, two of which are reported in
Table IV, the unseparated lymphocytes lysed both
targets after alloactivation; allostimulated T3- cells
were also cytotoxic for auto-Me and K562 whereas
the T3+ population was cytotoxic for auto-Me cells
but did not kill K562 cells. In all the experiments
both T3+ and T3- cells incorporated [3H]-TdR
after 6 days of stimulation by alloantigens.
These results indicate that both T3+ and T3-
cells, present in the initial Pt-PBL, can be allo-
activated to become cytotoxic against auto-Me
cells. Moreover, allostimulated T3+ cells lysed
auto-Me cells without showing NK-like activity on
K562 targets. Thus, the lysis of metastatic auto-Me
cells by alloactivated Pt-PBL represents the sum of
the cytotoxic activity of both T3+ and T3-
effectors.
Discussion
In the present paper we have confirmed on a larger
number of cases the capacity of alloantigens (MLC)
but not of auto-Me (MLTC), to activate Pt-PBL
with a lytic activity on metastatic auto-Me cells.
Lysis of fresh autologous tumours by Pt-PBL
stimulated in MLC has been reported for
melanomas and a variety of histologically different
human neoplasms (Zarling et al., 1978b; Strausser
et al., 1981; Fossati et al., 1982; Taylor & Bradley,
1983).
To explain these findings it has been suggested
by experiments on some animal and human
tumours that the lysis of tumour cells by T lympho-
cytes occurs through a cross-reaction between TAA
and normal histocompatibility antigens of allogenic
lymphocytes (Parmiani et al., 1979; Zarling & Bach,
1978a; Paciucci et al., 1980; Greenberg et al., 1981;
Kedar et al., 1982b; Taylor & Bradley, 1983).
According to this hypothesis, Pt-PBL are sensitized
in vivo to TAA and can be restimulated during
MLC where they may encounter the appropriate,
cross-reacting histocompatibility antigen. After
activation, therefore, these effectors would lyse
auto-Me cells though the alloantigen expressed as
alien on auto-Me targets. The results of the cold
target competition experiments with the stimulating
normal PBL, however, tend to exclude that the
target structure recognized by allostimulated Pt-
PBL on auto-Me cells are alien antigens, in keeping
with findings reported by others (Vanky et al.,
1982; Hurrell & Zarling, 1983).
The analysis of auto-Me cytotoxicity with MLC-
or MLTC-derived clones also tends to rule out the
possibility that the lysis of autologous tumour
targets by alloactivated Pt-PBL is due to cross-
reactivity between TAA and allogeneic MHC
determinants (Vose & White, 1983; De Vries &
Spits, 1984).
Alternatively, the lysis of autologous tumour cells
by allostimulated lymphocytes could be due to non-
specific effectors activated and expanded during
MLC and having the features of NK-like cells
rather than those of antitumour specific T cells
(Kedar et al., 1982a). To test this possibility, we
compared directly the capacity of alloantigens and
IL-2 to activate the PBL of 34 melanoma patients
to become cytotoxic to auto-Me and K562 cells. It
was found that both allo- and IL-2-stimulation
could trigger Pt-PBL to lyse auto-Me and K562 in
a high percentage of cases, thus suggesting that
both stimuli produced a similar effect. However,
cold target competition experiments indicated that
allostimulation induced a subpopulation of cyto-
toxic Pt-PBL predominantly directed against auto-
Me, since zero or weak inhibition of auto-Me lysis
was obtained with unlabelled K562 cells. On the
contrary, IL-2 seemed to activate a more homo-
geneous subpopulation of cytotoxic NK-like cells
which recognized target structures in common
between auto-Me and K562, as indicated by the
complete inhibition of auto-Me lysis obtained by
unlabelled K562 and auto-Me competitor cells. It
seems, therefore, that most metastatic melanoma
cells express at least -two different types of target
structures, one preferentially recognized by allo-
activated Pt-PBL and the other recognized by IL-2-
activated lymphocytes. This second type of
structure strongly cross-reacts with determinants
expressed by K562, operationally defined as NK-
like-sensitive sites.
These results may be explained by assuming that
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tumour specific cytotoxic cells and, with a lower
frequency, non-specific NK-like effectors, whereas
in the IL-2-activated effectors the NK-like killers
are the main cell subpopulation. Thus, the lysis of
auto-Me by allostimulated cells may represent a
combined effect of both specific and non-specific
killer cells (Muul & Gately, 1984).
The study of the phenotype of effector cells
activated by MLC or by IL-2 did not allow
dissection of the complex phenomenon since the
lymphocyte markers expressed after stimulation
were similar, although a reproducibly higher
frequency of OKMl+ cells was found in the IL-2-
activated cells. The results of cold target
competition experiments suggested that two types
of killers were generated by allostimulation, and,
therefore, we decided to physically isolate the
precursor cells and to study their properties. Both
T3+ and T3- FACS-separated subsets were found
to be activated by alloantigens and to lyse auto-Me;
T3- but not T3+ cells were also able to kill K562
targets. The lysis of auto-Me cells by alloactivated
precursors T3+ cells indicates that anti-melanoma
cytotoxic T cells may be present with a low
frequency but not easily detectable by using bulk
culture of the unstimulated lymphocyte population
of cancer patients. After alloactivation, these T cells
are expanded and lyse auto-Me cells possibly
through the recognition of TAA different from
those present on K562, as suggested by the failure
of T3+ cells to lyse K562 and also by cold target
competition experiments. Recent findings from this
and other laboratories (Vose & White, 1983; De
Vries & Spits, 1984; Knuth et al., 1984; Anichini et
al., 1985) on the successful isolation of cytotoxic T
lymphocyte clones showing auto-Me restricted
patterns of reactivity, support this interpretation.
Thus, although clones of auto-Me killer lympho-
cytes may be present in the Pt-PBL population, in
our experience the bulk population of Pt-PBL
cannot be stimulated by metastatic auto-Me cells
(Fossati et al., 1984). Allostimulation then
represents, at least for metastatic melanoma, a
useful procedure for activating antitumour T cells
present in the initial Pt-PBL with a frequency too
low to be detected in a MLTC, and for overcoming
the immunosuppressive activity of metastatic auto-
Me cells (Taramelli et al., 1984).
In addition to alloactivated T3+ cells, T3- PBL
were also found to lyse auto-Me targets, a result in
agreement with those reported by Vanky et al.
(1984), who found that T3- cells (or a low Percoll
density population) with or without activation by
Hu-IFN-a were responsible for the lysis of tumour
cells. Furthermore, Grimm et al. (1982) have shown
that T3- cells are the precursors of IL-2-activated
(LAK) effectors. In our study the activation and
proliferation of FACS-separated T3- cells by allo-
stimulation may be due to IL-2 released from the
irradiated pool of allogeneic lymphocytes.
The results of cold target inhibition experiments
and those on precursor cells would indicate that
allostimulation and IL-2 activation may work
through different mechanisms. We do not have a
clear explanation for that; it is possible that when
exogeneous IL-2 is added to PBL, activation of
non-specific NK-like population occurs which masks
the minor antitumour specific killer precursor cells.
During MLC, however, there may be a triggering
of T helper cells which, when activated, release IL-2
continuously and gradually thus activating both
antitumour specific and NK-like effectors.
This work was partially supported by Grants N.
83.00821.96 and 83.00900.96 of the Finalized Project
"Control of Tumor Growth" of Consiglio Nazionale delle
Ricerche, Rome, Italy.
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